FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 353:1363-1373 September 29, 2005 Number 13 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

The impact of influenza infection is felt globally each year when the disease develops in approximately 20 percent of the world's population. In the United States, influenza infections occur in epidemics each winter, generally between late December and early March. Recent events, including human cases of avian influenza, have heightened awareness of the threat of a pandemic and have spurred efforts to develop plans for its control.

Although vaccination is the primary strategy for the prevention of influenza, there are a number of likely scenarios for which vaccination is inadequate and effective antiviral agents would be of the utmost importance. . . . [Full Text of this Article]

Adamantanes and Neuraminidase Inhibitors

Development of Neuraminidase Inhibitor Molecules

Pharmacokinetics

Clinical Trials of Zanamivir and Oseltamivir

Treatment of Healthy Adults

Therapy in the Elderly

Therapy in Children

Prophylactic Efficacy of Zanamivir and Oseltamivir

Prophylaxis in Healthy Adults

Prophylaxis in High-Risk Elderly or Chronically Ill Populations

Prophylaxis in Children after Exposure

Safety and Dosage of Neuraminidase Inhibitors

Resistance to the Neuraminidase Inhibitors

Strategies for Treatment

Strategies for Prophylaxis

Avian Influenza and Pandemic Planning

Source Information

From the Departments of Pediatrics and Microbiology and Immunology, Weill Medical College of Cornell University, New York.

Address reprint requests to Dr. Moscona at the Department of Pediatrics, Box 309, Weill Medical College of Cornell University, 515 E. 71st St., Suite 600D, New York, NY 10021, or at anm2047@med.cornell.edu.

This article has been cited by other articles:

• Zeng, Q., Langereis, M. A., van Vliet, A. L. W., Huizinga, E. G., de Groot, R. J. (2008). Structure of coronavirus hemagglutinin-esterase offers insight into corona and influenza virus evolution. Proc. Natl. Acad. Sci. USA 105: 9065-9069 [Abstract] [Full Text]  
• Huang, I-C., Li, W., Sui, J., Marasco, W., Choe, H., Farzan, M. (2008). Influenza A Virus Neuraminidase Limits Viral Superinfection. J. Virol. 82: 4834-4843 [Abstract] [Full Text]  
• Nicoll, A (2008). Children, avian influenza H5N1 and preparing for the next pandemic. Arch. Dis. Child. 93: 433-438 [Abstract] [Full Text]  
• Carter, M. J. (2007). A rationale for using steroids in the treatment of severe cases of H5N1 avian influenza. J Med Microbiol 56: 875-883 [Abstract] [Full Text]  
• Hatakeyama, S., Sugaya, N., Ito, M., Yamazaki, M., Ichikawa, M., Kimura, K., Kiso, M., Shimizu, H., Kawakami, C., Koike, K., Mitamura, K., Kawaoka, Y. (2007). Emergence of Influenza B Viruses With Reduced Sensitivity to Neuraminidase Inhibitors. JAMA 297: 1435-1442 [Abstract] [Full Text]  
• Moscona, A., McKimm-Breschkin, J. (2007). News About Influenza B Drug Resistance That Cannot Be Ignored. JAMA 297: 1492-1493 [Full Text]  
• Aruksakunwong, O., Malaisree, M., Decha, P., Sompornpisut, P., Parasuk, V., Pianwanit, S., Hannongbua, S. (2007). On the Lower Susceptibility of Oseltamivir to Influenza Neuraminidase Subtype N1 than Those in N2 and N9. Biophys. J 92: 798-807 [Abstract] [Full Text]  
• Skowronski, D. M., Li, Y., Tweed, S. A., Tam, T. W.S., Petric, M., David, S. T., Marra, F., Bastien, N., Lee, S. W., Krajden, M., Brunham, R. C. (2007). Protective measures and human antibody response during an avian influenza H7N3 outbreak in poultry in British Columbia, Canada. CMAJ 176: 47-53 [Abstract] [Full Text]  
• Rameix-Welti, M. A., Agou, F., Buchy, P., Mardy, S., Aubin, J. T., Veron, M., van der Werf, S., Naffakh, N. (2006). Natural Variation Can Significantly Alter the Sensitivity of Influenza A (H5N1) Viruses to Oseltamivir. Antimicrob. Agents Chemother. 50: 3809-3815 [Abstract] [Full Text]  
• Ge, Q., Pastey, M., Kobasa, D., Puthavathana, P., Lupfer, C., Bestwick, R. K., Iversen, P. L., Chen, J., Stein, D. A. (2006). Inhibition of Multiple Subtypes of Influenza A Virus in Cell Cultures with Morpholino Oligomers. Antimicrob. Agents Chemother. 50: 3724-3733 [Abstract] [Full Text]  
• Gillim-Ross, L., Subbarao, K. (2006). Emerging Respiratory Viruses: Challenges and Vaccine Strategies. Clin. Microbiol. Rev. 19: 614-636 [Abstract] [Full Text]  
• Singh, A M, Busse, W W (2006). Asthma exacerbations {middle dot} 2: Aetiology.. Thorax 61: 809-816 [Abstract] [Full Text]  
• Bartlett, J. G. (2006). Planning for Avian Influenza. ANN INTERN MED 145: 141-144 [Abstract] [Full Text]  
• Regoes, R. R., Bonhoeffer, S. (2006). Emergence of drug-resistant influenza virus: population dynamical considerations.. Science 312: 389-391 [Abstract] [Full Text]  
• Germann, T. C., Kadau, K., Longini, I. M. Jr., Macken, C. A. (2006). From the Cover: Mitigation strategies for pandemic influenza in the United States. Proc. Natl. Acad. Sci. USA 103: 5935-5940 [Abstract] [Full Text]  
• (2006). High Levels of Adamantane Resistance Among Influenza A (H3N2) Viruses and Interim Guidelines for Use of Antiviral Agents--United States, 2005-06 Influenza Season. JAMA 295: 881-882 [Full Text]  
• Weinstock, D. M., Zuccotti, G. (2006). Adamantane Resistance in Influenza A. JAMA 295: 934-936 [Full Text]  
• Gostin, L. O. (2006). Medical Countermeasures for Pandemic Influenza: Ethics and the Law. JAMA 295: 554-556 [Full Text]  
• Moscona, A. (2005). Oseltamivir Resistance -- Disabling Our Influenza Defenses. NEJM 353: 2633-2636 [Full Text]  
• de Jong, M. D., Thanh, T. T., Khanh, T. H., Hien, V. M., Smith, G. J.D., Chau, N. V., Cam, B. V., Qui, P. T., Ha, D. Q., Guan, Y., Peiris, J.S. M., Hien, T. T., Farrar, J. (2005). Oseltamivir Resistance during Treatment of Influenza A (H5N1) Infection. NEJM 353: 2667-2672 [Abstract] [Full Text]  
• Tanne, J. H. (2005). Roche considers licensing companies to make oseltamivir. BMJ 331: 981-981 [Full Text]  
• Macfarlane, J. T, Lim, W. S. (2005). Bird flu and pandemic flu. BMJ 331: 975-976 [Full Text]